Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging.
Traumatic brain injury (TBI) is an epigenetic risk factor for Alzheimer's disease (AD). To test the hypothesis that TBI contributes to the onset and/or progression of AD-like beta-amyloid peptide (Abeta) deposits, we studied the long-term effects of TBI in transgenic mice that overexpress human Abeta from a mutant Abeta precursor protein (APP) minigene driven by a platelet derived (PD) growth factor promoter (PDAPP mice). TBI was induced in 4-month-old PDAPP and wild type (WT) mice by controlled cortical impact (CCI). Because Abeta begins to deposit progressively in the PDAPP brain by 6 months, we examined WT and PDAPP mice at 2, 5, and 8 months after TBI or sham treatment (i.e., at 6, 9, and 12 months of age). Hippocampal atrophy in the PDAPP mice was more severe ipsilateral versus contralateral to TBI, and immunohistochemical studies with antibodies to different Abeta peptides demonstrated a statistically significant reduction in hippocampus and cingulate cortex Abeta deposits ipsilateral versus contralateral to CCI in 9-12 month-old PDAPP mice. Hippocampal atrophy and reduced Abeta deposits were not seen in hippocampus or cingulate cortex of sham-injured PDAPP mice or in any WT mice. These data suggest that the vulnerability of brain cells to Abeta toxicity increases and that the accumulation of Abeta deposits decrease in the penumbra of CCI months after TBI. Thus, in addition to providing unique opportunities for elucidating genetic mechanisms of AD, transgenic mice that recapitulate AD pathology also may be relevant animal models for investigating the poorly understood role that TBI and other epigenetic risk factors play in the onset and/or progression of AD.
The Center for Neurodegenerative Disease Research, Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4283, USA.
Y
Y
Nakagawa
M
M
Nakamura
T K
TK
McIntosh
A
A
Rodriguez
J A
JA
Berlin
D H
DH
Smith
K E
KE
Saatman
R
R
Raghupathi
J
J
Clemens
T C
TC
Saido
M L
ML
Schmidt
V M
VM
Lee
J Q
JQ
Trojanowski
D000544:Alzheimer Disease / Q000453:epidemiology / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D000818:Animals; D001284:Atrophy; D001930:Brain Injuries / Q000150:complications*; D004195:Disease Models, Animal; D005260:Female; D015870:Gene Expression; D006624:Hippocampus / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D010052:Ovariectomy; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D011401:Promoter Regions, Genetic; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000502:physiology; D012307:Risk Factors; D014945:Wound Healing / Q000235:genetics; D014949:Wounds, Nonpenetrating
D016229:Amyloid beta-Peptides; D010982:Platelet-Derived Growth Factor; D011993:Recombinant Fusion Proteins